Dr. Iyengar on the Benefit of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer After T-DM1
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
HER2+ mBC Trials in Progress and Other Exciting Prospects on the Horizon
Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.
Considering Pulmonary Status: Monitoring for Interstitial Lung Disease
Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.
New Data and Guidelines Concerning HER2+ mBC Therapy Sequencing
Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.
The Impact of Brain Metastases on Treatment Selection in Patients with HER2+ mBC
Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.
Review of Key Data Supporting Recent Developments in the HER2+ mBC Landscape
An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.
The Current Standard-of-Care for Patients with HER2+ Metastatic Breast Cancer
Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.
Considering Novel Therapy for HER2+ Metastatic Breast Cancer
A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
Patient Profile 2: 3L Therapy for Triple-Positive mBC
Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.
Patient Profile 2: Second-Line Therapy for Triple-Positive mBC
Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.
Patient Profile 2: Patient with Triple-Positive mBC
Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.
Patient Profile 1: Sequencing Therapies in HER2+ mBC
Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
Patient Profile 1: Second-Line Therapy for HER2+ mBC
Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.
Patient Profile 1: Frontline Therapy for HER2+ mBC
Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.
Recent Trial Data in HER2+ Metastatic Breast Cancer
Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.
Selecting and Sequencing Therapy for HER2+ Breast Cancer
Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.
HER2+ Breast Cancer: Overview of the Treatment Armamentarium
Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.
Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.
Treatment Advances in HR+/HER2- MBC
Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.
Sequencing Therapy in HR+/HER2- MBC
Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.
PI3K Therapy for HR+/HER2- MBC: Metabolic Syndrome
Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.
Managing Patients With HR+ MBC on PI3K Therapy
Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.
PI3K Inhibitors for PIK3CA-Mutated HR+ MBC
Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.
CDK4/6 Treatment Selection for HR+/HER2- MBC
The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.
Comparison of CDK4/6 Therapies for HR+/HER2- MBC
Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.
HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities
Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.
MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy
Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.
Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data
Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.
Frontline Treatment Approaches for HR+/HER2- MBC
A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.
HR+ MBC: Prognostic Factors and Treatment Planning
Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.
Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
2 Clarke Drive Cranbury, NJ 08512